Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.880,05
-0,02%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Annexon Inc (ANNX) Annexon Inc (ANNX) Notizie

Annexon Inc

ANNX
5,10
0,44 (9,44%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
16/4/202415:00GLOBETurnstone Biologics Appoints William Waddill to its Board of..
21/2/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202421:15EDGAR2Form 144 - Report of proposed sale of securities
20/2/202421:12EDGAR2Form 144 - Report of proposed sale of securities
15/2/202402:46EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202401:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202401:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202401:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202421:45EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202401:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202400:57EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202422:24EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/2/202421:45EDGAR2Form 144 - Report of proposed sale of securities
12/2/202421:41EDGAR2Form 144 - Report of proposed sale of securities
12/2/202421:39EDGAR2Form 144 - Report of proposed sale of securities
23/1/202423:00EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
23/1/202422:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202422:09EDGAR2Form 8-K - Current report
08/1/202402:00GLOBEAnnexon Outlines 2024 Priorities with Late-Stage Clinical..
29/12/202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202322:50EDGAR2Form 144 - Report of proposed sale of securities
27/12/202312:30GLOBEAnnexon Biosciences to Present at the 42nd Annual J.P...
22/12/202323:28EDGAR2Form 8-K/A - Current report: [Amend]
21/12/202322:09EDGAR2Form 8-K - Current report
21/12/202322:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/12/202323:27GLOBEAnnexon Announces Pricing of $125.0 Million Underwritten..
20/12/202323:24EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
20/12/202323:17EDGAR2Form 8-K - Current report
20/12/202323:10GLOBEAnnexon Outlines Global Registrational Program for ANX007 in..
20/12/202323:08GLOBEAnnexon Reports Phase 1 Results for ANX1502, its Oral Small..
18/12/202322:01GLOBEAnnexon Reports Inducement Grants to New Employees Under..
22/11/202322:01GLOBEAnnexon Biosciences to Participate in the 6th Annual..
13/11/202322:10EDGAR2Form 8-K - Current report
13/11/202312:30GLOBEAnnexon Reports Significant Progress with its Priority..
09/11/202312:30GLOBEAnnexon Biosciences to Participate in 2023 Jefferies London..
24/10/202322:30EDGAR2Form 8-K - Current report
24/10/202312:30GLOBEAnnexon Receives PRIME Designation from the EMA for ANX007..
18/10/202322:01GLOBEAnnexon Reports Inducement Grants to New Employees Under..
11/10/202322:44EDGAR2Form 8-K - Current report
10/10/202312:30GLOBEAnnexon Announces Clinical and Regulatory Progress for..
19/9/202312:30GLOBEAnnexon Biosciences to Participate in the 2023 Cantor Global..
18/9/202322:01GLOBEAnnexon Reports Inducement Grant to New Employee Under..
07/8/202322:12EDGAR2Form 8-K - Current report
07/8/202322:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202312:30GLOBEAnnexon Highlights Recent Pipeline and Business Progress and..
02/8/202323:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202323:06EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/8/202322:01GLOBEAnnexon Reports Inducement Grant to New Employee Under..
Apertura: 4,75 Min: 4,69 Max: 5,06
Chiusura: 4,66

La tua Cronologia

NASDAQ
ANNX
Annexon
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network